Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 7, 2017; 23(33): 6155-6163
Published online Sep 7, 2017. doi: 10.3748/wjg.v23.i33.6155
Published online Sep 7, 2017. doi: 10.3748/wjg.v23.i33.6155
Total | Group A:No chromosome aberration1 | Group B:t(11;18) positive | Group C:Extra copies of MALT1 | |
Treatment | ||||
Eradication alone | 85 | 62 | 3 | 20 |
RT alone | 23 | 8 | 15 | 0 |
Chemotherapy alone | 8 | 3 | 2 | 3 |
RT and chemotherapy | 2 | 1 | 0 | 1 |
Eradication RT | 17 | 6 | 5 | 6 |
Eradication and chemotherapy | 3 | 2 | 0 | 1 |
Eradication and RT and chemotherapy | 2 | 1 | 1 | 0 |
None | 6 | 5 | 1 | 0 |
Outcome | ||||
Live without disease | 103 | 61 | 21 | 21 |
Live with disease | 33 | 20 | 5 | 8 |
Live, unknown disease status | 6 | 5 | 1 | 0 |
Dead by other cause | 3 | 1 | 0 | 2 |
Dead by MALT lymphoma | 1 | 1 | 0 | 0 |
Follow-up period (mean ± SD, yr) | 3.9 ± 3.3 | 3.9 ± 3.1 | 5.1 ± 4.5 | 2.9 ± 2.2 |
- Citation: Iwamuro M, Takenaka R, Nakagawa M, Moritou Y, Saito S, Hori S, Inaba T, Kawai Y, Toyokawa T, Tanaka T, Yoshino T, Okada H. Management of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene. World J Gastroenterol 2017; 23(33): 6155-6163
- URL: https://www.wjgnet.com/1007-9327/full/v23/i33/6155.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i33.6155